GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (NEOE:BMND) » Definitions » LT-Debt-to-Total-Asset

Biomind Labs (NEOE:BMND) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Biomind Labs's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Biomind Labs's long-term debt to total assets ratio stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).


Biomind Labs LT-Debt-to-Total-Asset Historical Data

The historical data trend for Biomind Labs's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs LT-Debt-to-Total-Asset Chart

Biomind Labs Annual Data
Trend Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
- - -

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biomind Labs LT-Debt-to-Total-Asset Calculation

Biomind Labs's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/0.099
=

Biomind Labs's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=0/0.072
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomind Labs  (NEOE:BMND) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Biomind Labs LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Biomind Labs's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomind Labs Business Description

Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs Headlines

No Headlines